Poseida Therapeutics (PSTX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Platform technology and differentiation

• Utilizes a proprietary, non-viral genetic engineering toolkit, including piggyBac transposon and Cas-CLOVER gene editor, enabling high-fidelity gene editing and unique CAR-T stem cell memory cell enrichment.

• Allogeneic CAR-T products are uniquely rich in T stem cell memory cells, which are linked to greater depth and durability of clinical responses.

• Non-viral approach allows for features in CAR-T products not achievable with viral vectors, setting the technology apart in the field.

Strategic partnerships and funding

• Extensive partnership with Roche in heme malignancies, including two clinical-stage assets and a broad research collaboration.

• Newer collaboration with Astellas focuses on solid tumors, combining proprietary CAR-T production with convertible CAR technology.

• Over $400 million raised through partnerships in the past three years, supporting operations with non-dilutive funding.

Clinical pipeline and data updates

• Lead BCMA-targeted CAR-T program for multiple myeloma showed an 82% overall response rate and 100% in BCMA-naïve patients, with a strong safety profile and no severe adverse events.

• Upcoming data updates for all three clinical programs, including BCMA, MUC1-C (solid tumors), and dual CAR (CD19/CD20) for lymphoma, expected before year-end.

• MUC1-C program is a basket study in various epithelial cancers, with adjustments in lymphodepletion strategy to enhance efficacy.